参考文献/References:
[1] Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet,2011,378(9785):31-40.
[2] Lin Y, Li H, Lan X, et al. Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus[J]. Sci World J,2013,2013: 209428.
[3] Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression[J]. Circ Res,2014,114(9):1483-1499.
[4] Miki T, Yuda S, Kouzu H, et al. Diabetic cardiomyopathy:pathophysiology and clinical features[J]. Heart Fail Rev,2013,18(2):149-166.
[5] Ayhan S, Ozturk S, Alcelik A, et al. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose[J]. J Interv Card Electrophysiol,2012,35(3): 247-252; discussion 252.
[6] Akyel A, Oksuz F, Karadeniz M, et al. Atrial electromechanical delay in type 2 diabetes mellitus[J]. Wien Klin Wochenschr,2014,126(3-4):101-105.
[7] Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose[J]. Am J Cardiol,2010,106(11):1615-1620.
[8] Kadappu KK, Boyd A, Eshoo S, et al. Changes in left atrial volume in diabetes mellitus:more than diastolic dysfunction[J]. Eur Heart J Cardiovasc Imaging,2012,13(12):1016-1023.
[9] Liu C, Fu H, Li J, et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits[J]. Anadolu Kardiyol Derg,2012,12(7):543-550.
[10] Goudis CA, Korantzopoulos P, Ntalas IV, et al. Diabetes mellitus and atrial fibrillation:pathophysiological mechanisms and potential upstream therapies[J]. Int J Cardiol,2015,184:617-622.
[11] Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation[J]. Circulation,2012,125(2): 216-225.
[12] Guo L, Jiang F, Tang YT, et al. The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease[J]. Diabetes Technol Ther,2014,16(4):224-234.
[13] Gong X, Wang P, Wu Q, et al. Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W)transgenic mouse of dilated cardiomyopathy[J]. Eur J Cell Biol,2016,95(1):57-67.
[14] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J]. Diabetes Care,2012,35(6):1364-1379.
[15] Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus:a population-based dynamic cohort and in vitro studies[J]. Cardiovasc Diabetol,2014,13:123.
[16] Azimova K, San JZ, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs[J]. Ochsner J,2014,14(4):616-632.
[17] Yamazaki M, Avula UM, Bandaru K, et al. Acute regional left atrial ischemia causes acceleration of atrial drivers during atrial fibrillation[J]. Heart Rhythm,2013,10(6):901-909.
[18] Latini R, Staszewsky L, Sun JL, et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance:the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial[J]. Am Heart J,2013,166(5):935-940.e1.
[19] Gu J, Liu X, Wang QX, et al. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models[J]. J Mol Cell Cardiol,2013, 65:1-8.
[20] Gu J, Hu W, Liu X. Pioglitazone improves potassium channel remodeling induced by angiotensin Ⅱ in atrial myocytes[J]. Med Sci Monit Basic Res,2014,20:153-160.
[21] Liu B, Wang J, Wang G. Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients[J]. Int Heart J,2014,55(6):499-505.
[22] Swartz MF, Fink GW, Sarwar MF, et al. Elevated pre-operative serum peptides for collagen Ⅰand Ⅲsynthesis result in post-surgical atrial fibrillation[J]. J Am Coll Cardiol,2012,60(18):1799-1806.
[23] Xu D, Murakoshi N, Igarashi M, et al. PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model[J]. J Cardiovasc Electrophysiol,2012,23(2):209-217.
[24] Liu T, Zhao H, Li J, et al. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits[J]. Cardiovasc Ther,2014,32(4):178-183.
[25] Chao TF, Leu HB, Huang CC, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes[J]. Int J Cardiol,2012,156(2):199-202.
[26] Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus[J]. Europace,2011,13(9):1256-1261.
[27] Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy[J]. Curr Diab Rep,2014,14(5):483.
[28] Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report[J]. Cardiovasc Diabetol,2013,12:73.
[29] Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials[J]. Diab Vasc Dis Res,2015,12(2):90-100.
[30] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015,373(22):2117-2128.
相似文献/References:
[1]张源,王群山.达比加群酯在器质性心脏病的心房颤动中的应用进展[J].心血管病学进展,2016,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.008]
ZHANG Yuan,WANG Qunshan.Advance of Research about Dabigatran Etexliate in
Organic Heart Disease with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.008]
[2]杨震,李晶,贾绍斌.不明原因脑卒中患者心房颤动的筛查[J].心血管病学进展,2016,(1):69.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.018]
YANG Zhen,LI Jing,JIA Shaobin.Identification of Atrial Fibrillation in Patients with Cryptogenic Stroke[J].Advances in Cardiovascular Diseases,2016,(4):69.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.018]
[3]郑涛,综述,凌智瑜,等.心外膜脂肪组织与心房颤动[J].心血管病学进展,2016,(4):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
ZHENG Tao,LING Zhiyu.Epicardial Adipose Tissue and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
[4]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(4):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[5]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[6]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[7]张明 王敬萍.Nur77和GRP78与糖尿病心肌缺血再灌注损伤的关系研究[J].心血管病学进展,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
ZHANG Ming Wang Jingping.Relationship between Nur77 and GRP78 and Myocardial Ischemia-reperfusion Injury in Diabetic Patients[J].Advances in Cardiovascular Diseases,2020,(4):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
[8]麦尔耶姆·瓦热斯 罗心平 周鹏.糖尿病与心力衰竭：2型糖尿病是心力衰竭的独立危险因素？[J].心血管病学进展,2020,(7):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
Maieryemu·Waresi,LUO Xinping,ZHOU Peng.Diabetes and Heart Failure: Is Type 2 Diabetes an Independent Risk Factor for Heart Failure?[J].Advances in Cardiovascular Diseases,2020,(4):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
[9]廖丽萍 周跟东 张晓红.血清甘油三酯葡萄糖乘积指数与代谢性疾病的研究进展[J].心血管病学进展,2020,(11):1189.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[10]高婧晗 刘飞 杨晓蕾 夏云龙.钙离子稳态的调控在糖尿病相关心房颤动中的作用[J].心血管病学进展,2021,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
GAO Jinghan,LIU Fei,YANG Xiaolei,et al.Regulation of Calcium Homeostasis in Diabetes-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]